245 related articles for article (PubMed ID: 8973693)
1. Longitudinal analysis of serial measurements of free and total PSA among men with and without prostatic cancer.
Pearson JD; Luderer AA; Metter EJ; Partin AW; Chan DW; Fozard JL; Carter HB
Urology; 1996 Dec; 48(6A Suppl):4-9. PubMed ID: 8973693
[TBL] [Abstract][Full Text] [Related]
2. Comparison of three assays for total serum prostate-specific antigen and percentage of free prostate-specific antigen in predicting prostate histology.
Roehrborn CG; Gregory A; McConnell JD; Sagalowsky AI; Wians FH
Urology; 1996 Dec; 48(6A Suppl):23-32. PubMed ID: 8973696
[TBL] [Abstract][Full Text] [Related]
3. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL.
Kwiatkowski MK; Recker F; Piironen T; Pettersson K; Otto T; Wernli M; Tscholl R
Urology; 1998 Sep; 52(3):360-5. PubMed ID: 9730444
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of prostAsure index in the detection of prostate cancer: a preliminary report.
Babaian RJ; Fritsche HA; Zhang Z; Zhang KH; Madyastha KR; Barnhill SD
Urology; 1998 Jan; 51(1):132-6. PubMed ID: 9457308
[TBL] [Abstract][Full Text] [Related]
5. A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates: the best case scenario.
Prestigiacomo AF; Lilja H; Pettersson K; Wolfert RL; Stamey TA
J Urol; 1996 Aug; 156(2 Pt 1):350-4. PubMed ID: 8683677
[TBL] [Abstract][Full Text] [Related]
6. High serum prostate-specific antigen levels in the absence of prostate cancer in Middle-Eastern men: the clinician's dilemma.
Kehinde EO; Sheikh M; Mojimoniyi OA; Francis I; Anim JT; Nkansa-Dwamena D; Al-Awadi KA
BJU Int; 2003 May; 91(7):618-22. PubMed ID: 12699471
[TBL] [Abstract][Full Text] [Related]
7. Prostatic volume and ratio of free-to-total prostate specific antigen in patients with prostatic cancer or benign prostatic hyperplasia.
Haese A; Graefen M; Noldus J; Hammerer P; Huland E; Huland H
J Urol; 1997 Dec; 158(6):2188-92. PubMed ID: 9366341
[TBL] [Abstract][Full Text] [Related]
8. The ratio of free to total serum prostate specific antigen and its use in differential diagnosis of prostate carcinoma in Japan.
Egawa S; Soh S; Ohori M; Uchida T; Gohji K; Fujii A; Kuwao S; Koshiba K
Cancer; 1997 Jan; 79(1):90-8. PubMed ID: 8988731
[TBL] [Abstract][Full Text] [Related]
9. Free to total prostate-specific antigen (PSA) ratio improves the discrimination between prostate cancer and benign prostatic hyperplasia (BPH) in the diagnostic gray zone of 1.8 to 10 ng/mL total PSA.
Van Cangh PJ; De Nayer P; De Vischer L; Sauvage P; Tombal B; Lorge F; Wese FX; Opsomer R
Urology; 1996 Dec; 48(6A Suppl):67-70. PubMed ID: 8973703
[TBL] [Abstract][Full Text] [Related]
10. Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system.
Vashi AR; Wojno KJ; Henricks W; England BA; Vessella RL; Lange PH; Wright GL; Schellhammer PF; Weigand RA; Olson RM; Dowell BL; Borden KK; Oesterling JE
Urology; 1997 Jan; 49(1):19-27. PubMed ID: 9000179
[TBL] [Abstract][Full Text] [Related]
11. Clinical implications of free-to-total immunoreactive prostate-specific antigen ratios.
Wymenga LF; Duisterwinkel FJ; Groenier K; Visser-van Brummen P; Marrink J; Mensink HJ
Scand J Urol Nephrol; 2000 Jun; 34(3):181-7. PubMed ID: 10961472
[TBL] [Abstract][Full Text] [Related]
12. Free and complexed prostate-specific antigen serum ratios to predict probability of primary prostate cancer and benign prostatic hyperplasia.
Marley GM; Miller MC; Kattan MW; Zhao G; Patton KP; Vessella RL; Wright GL; Schellhammer PF; Veltri RW
Urology; 1996 Dec; 48(6A Suppl):16-22. PubMed ID: 8973695
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the clinical value of complexed PSA and total PSA in the discrimination between benign prostatic hyperplasia and prostate cancer.
Froehner M; Hakenberg OW; Koch R; Schmidt U; Meye A; Wirth MP
Urol Int; 2006; 76(1):27-30. PubMed ID: 16401917
[TBL] [Abstract][Full Text] [Related]
14. Free and total PSA in the diagnosis of prostate cancer.
Filella X; Alcover J; Molina R; Rodríguez A; Carretero P; Ballesta AM
Tumour Biol; 1997; 18(6):332-40. PubMed ID: 9372866
[TBL] [Abstract][Full Text] [Related]
15. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia.
Roehrborn CG; Boyle P; Gould AL; Waldstreicher J
Urology; 1999 Mar; 53(3):581-9. PubMed ID: 10096388
[TBL] [Abstract][Full Text] [Related]
16. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.
Stamey TA; Johnstone IM; McNeal JE; Lu AY; Yemoto CM
J Urol; 2002 Jan; 167(1):103-11. PubMed ID: 11743285
[TBL] [Abstract][Full Text] [Related]
17. [Clinical usefulness of free PSA/total PSA ratio in the early diagnosis of prostatic cancer].
Laguna Pes MP; Guinda Sevillano C; Zazo Romojaro A; Domínguez J; García Luzón A; Borrego Hernando J; Gimeno Collado A
Arch Esp Urol; 2000 May; 53(4):333-41. PubMed ID: 10900763
[TBL] [Abstract][Full Text] [Related]
18. The effect of high grade prostatic intraepithelial neoplasia on serum total and percentage of free prostate specific antigen levels.
Ramos CG; Carvahal GF; Mager DE; Haberer B; Catalona WJ
J Urol; 1999 Nov; 162(5):1587-90. PubMed ID: 10524873
[TBL] [Abstract][Full Text] [Related]
19. Free/total PSA ratio improves differentiation of benign and malignant disease of the prostate: critical analysis of two different test populations.
Veltri RW; Miller MC
Urology; 1999 Apr; 53(4):736-45. PubMed ID: 10197849
[TBL] [Abstract][Full Text] [Related]
20. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]